Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q2 EPS of $4.51, $0.06 better than the analyst estimate of $4.45. Revenue for the quarter came in at $957.32 million versus the consensus estimate of $941.99 million.

For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.